TBP — Tetra Bio Pharma Income Statement
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro Cap
Annual income statement for Tetra Bio Pharma, fiscal year end - November 30th, CAD millions except per share, conversion factor applied.
2017 November 30th | R2018 November 30th | R2019 November 30th | 2020 November 30th | 2021 November 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Operating Interest Expense / Income | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 6.68 | 7.84 | 13.1 | 20.9 | 50.6 |
| Operating Profit | -6.68 | -7.84 | -13.1 | -20.9 | -50.6 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -6.7 | -7.84 | -13.1 | -21.2 | -52.2 |
| Net Income After Taxes | -6.7 | -7.84 | -13.1 | -21.2 | -52.2 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -6.23 | -7.57 | -15.3 | -26.5 | -52.2 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -6.23 | -7.57 | -15.3 | -26.5 | -52.2 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.054 | -0.079 | -0.069 | -0.08 | -0.062 |